top of page
Home: Welcome
Home: About Us

WELCOME TO MEDINECT OPHTHO

​

Your medical innovations connected
with preclinical experts

​

We have a dedicated team who work closely with you to ensure you get the most out of your preclinical studies. We ensure your study meets the goals you set for each experiment through better study design using better research models.

​

Home: Our Technology

WHO WE ARE

​

Drug development is challenging, especially in a new therapeutic area. Our focus is solely on retinal disease and we have experts to help you through difficult study designs and technical scientists who have been carrying out the procedures for years and you can trust. MediNect are a preclinical CRO that provides agile research solutions to advance your retinal disease therapy.

​

Our expertise is built on 25 years of academic research and development. With access to the UK’s second-largest preclinical ophthalmology suite, our facilities are state-of-the-art. Our team is dedicated to providing clients with deep discussions to answer their needs, and we pride ourselves on communication that suits you.

​

​

​

Ophthalmology CRO
ELISA
In vitro retinal organoids
Retinal histology

EARLY-STAGE PROOF OF CONCEPT SERVICE

Customised POC studies

Learn how we work closely with you to plan your early proof of concept work

LATE-STAGE PROOF OF CONCEPT SERVICE

Regulatory POC studies

We provide robust studies with clear well defined endpoints to ensure compliance for regulators 

MECHANISM OF ACTION SERVICE

Investigatory research

We work alongside you bringing in subject experts to the table to help you understand your therapeutic further

ADME

PK/PD and distribution studies

Delivery via oral gavage, subcutaneous, intravitreal, sublingual, subconjunctival, sub-retinal, intraperitoneal
and intravenous.

​

As well as PK analysis - we offer distribution studies to determine the location of your therapeutic in the eye
sub-compartments

bottom of page